PBI-1402 is a non-toxic, well-defined low molecular weight synthetic hematopoietic growth stimulant. PBI-1402 promotes the proliferation and maturation of hematopoietic progenitors (myeloid and erythroid populations) yielding a biological efficacy comparable to G-CSF, GM-CSF and EPO in in vitro human bone marrow cell proliferation and colony formation assays. An additive effect is observed when PBI-1402 is combined with G-CSF, GM-CSF and EPO. In human bone marrow colony assay, PBI-1402 enhances the differentiation of pluripotent stem cells: CFU-GEMM, CFU-GM with a predominant effect on BFU-E. Furthermore, PBI-1402 exerts its activity via a different mechanism of action than EPO and stem cell factor (SCF) and at an earlier stage on more immature hematopoietic progenitors. PBI-1402 is targeted as an adjunct to cancer chemo/radiotherapy, bone marrow transplantation and diseases involving neutropenia and anemia.

Topics:
central nervous system stimulants, molecular mass, partial breast irradiation, penile brachial index, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, recombinant granulocyte colony stimulating factor, recombinant granulocyte-macrophage colony-stimulating factors, anemia, bone marrow transplantation

Disclosures: All authors except those noted below, are salaried employees of the therapeutic business unit of ProMetic Life Sciences Inc. (PLI). PLI is a publicly traded company listed on the Toronto Stock Exchance. D.C. Roy, M.J. Morin and G. Krosl are under contract with PLI since 2003.

Author notes

*

Corresponding author

2006, The American Society of Hematology
2006
Sign in via your Institution